PMID- 30979652
OWN - NLM
STAT- MEDLINE
DCOM- 20191220
LR  - 20231213
IS  - 1532-818X (Electronic)
IS  - 0196-0709 (Linking)
VI  - 40
IP  - 4
DP  - 2019 Jul-Aug
TI  - Expression of vimentin (VIM) and metastasis-associated 1 (MTA1) protein in 
      laryngeal squamous cell carcinoma are associated with prognostic outcome of 
      patients.
PG  - 487-493
LID - S0196-0709(19)30256-X [pii]
LID - 10.1016/j.amjoto.2019.04.002 [doi]
AB  - PURPOSE: Laryngeal squamous cell carcinoma (LSCC), a common type of head and neck 
      cancer, is associated with high rates of metastasis and recurrence. In this 
      study, we investigated the potential combinatorial prognostic value of NOTCH1, 
      Vimentin (VIM), and Metastasis-associated 1 (MTA1) protein in LSCC, using 
      immunohistochemistry. MATERIALS AND METHODS: Tissue specimens from 69 patients 
      with LSCC were immunohistochemically evaluated for the protein expression of 
      NOTCH1, VIM, and MTA1. Then, biostatistical analysis was performed, in order to 
      assess the prognostic value of the expression of each one of these proteins. 
      RESULTS: NOTCH1 expression status was not a significant prognosticator in LSCC, 
      as shown in Kaplan-Meier survival analysis. On the contrary, both VIM and MTA1 
      seem to have an important prognostic potential, independently of TNM staging and 
      histological grade of the tumor. In fact, positive VIM expression was shown to 
      predict patients' relapse and poor outcome regarding patients' overall survival, 
      in contrast with MTA1, the positive expression of which predicts higher 
      disease-free survival (DFS) and overall survival (OS) rates in LSCC. CONCLUSIONS: 
      VIM and MTA1 constitute potential tumor biomarkers in LSCC and could be 
      integrated into a multiparametric prognostic model. Undoubtedly, their prognostic 
      value needs further validation in larger cohorts of LSCC patients.
CI  - Copyright (c) 2019 Elsevier Inc. All rights reserved.
FAU - Karamagkiolas, Sotirios
AU  - Karamagkiolas S
AD  - First Department of Otolaryngology, Athens General Hospital "Hippokration", 
      Faculty of Medicine, National and Kapodistrian University of Athens, Athens, 
      Greece. Electronic address: sotiriskar13@windowslive.com.
FAU - Giotakis, Ioannis
AU  - Giotakis I
AD  - First Department of Otolaryngology, Athens General Hospital "Hippokration", 
      Faculty of Medicine, National and Kapodistrian University of Athens, Athens, 
      Greece.
FAU - Kyrodimos, Efthimios
AU  - Kyrodimos E
AD  - First Department of Otolaryngology, Athens General Hospital "Hippokration", 
      Faculty of Medicine, National and Kapodistrian University of Athens, Athens, 
      Greece.
FAU - Giotakis, Evangelos I
AU  - Giotakis EI
AD  - First Department of Otolaryngology, Athens General Hospital "Hippokration", 
      Faculty of Medicine, National and Kapodistrian University of Athens, Athens, 
      Greece.
FAU - Kataki, Agapi
AU  - Kataki A
AD  - First Department of Propaedeutic Surgery, Athens General Hospital "Hippokration", 
      Faculty of Medicine, National and Kapodistrian University of Athens, Athens, 
      Greece.
FAU - Karagianni, Fani
AU  - Karagianni F
AD  - First Department of Propaedeutic Surgery, Athens General Hospital "Hippokration", 
      Faculty of Medicine, National and Kapodistrian University of Athens, Athens, 
      Greece.
FAU - Lazaris, Andreas M
AU  - Lazaris AM
AD  - Department of Vascular Surgery, University General Hospital "Attikon", Faculty of 
      Medicine, National and Kapodistrian University of Athens, Athens, Greece.
LA  - eng
PT  - Journal Article
DEP - 20190403
PL  - United States
TA  - Am J Otolaryngol
JT  - American journal of otolaryngology
JID - 8000029
RN  - 0 (Biomarkers, Tumor)
RN  - 0 (MTA1 protein, human)
RN  - 0 (NOTCH1 protein, human)
RN  - 0 (Receptor, Notch1)
RN  - 0 (Repressor Proteins)
RN  - 0 (Trans-Activators)
RN  - 0 (Vimentin)
SB  - IM
MH  - Adult
MH  - Aged
MH  - Aged, 80 and over
MH  - Biomarkers, Tumor/genetics/metabolism
MH  - Female
MH  - *Gene Expression
MH  - Humans
MH  - Immunohistochemistry
MH  - Laryngeal Neoplasms/diagnosis/*genetics/*metabolism/mortality
MH  - Male
MH  - Middle Aged
MH  - Prognosis
MH  - Receptor, Notch1/genetics/metabolism
MH  - Repressor Proteins/*genetics/*metabolism
MH  - Squamous Cell Carcinoma of Head and 
      Neck/diagnosis/*genetics/*metabolism/mortality
MH  - Survival Rate
MH  - Trans-Activators/*genetics/*metabolism
MH  - Vimentin/*genetics/*metabolism
OTO - NOTNLM
OT  - Head and neck cancer
OT  - Laryngeal cancer
OT  - Prognostic tumor biomarker
EDAT- 2019/04/14 06:00
MHDA- 2019/12/21 06:00
CRDT- 2019/04/14 06:00
PHST- 2019/03/23 00:00 [received]
PHST- 2019/03/30 00:00 [revised]
PHST- 2019/04/02 00:00 [accepted]
PHST- 2019/04/14 06:00 [pubmed]
PHST- 2019/12/21 06:00 [medline]
PHST- 2019/04/14 06:00 [entrez]
AID - S0196-0709(19)30256-X [pii]
AID - 10.1016/j.amjoto.2019.04.002 [doi]
PST - ppublish
SO  - Am J Otolaryngol. 2019 Jul-Aug;40(4):487-493. doi: 10.1016/j.amjoto.2019.04.002. 
      Epub 2019 Apr 3.